表紙
市場調査レポート

B型血友病:パイプライン分析

Hemophilia B - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232835
出版日 ページ情報 英文 122 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
B型血友病:パイプライン分析 Hemophilia B - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 122 Pages
概要

B型血友病は、血液凝固第IX因子の不足により生じる、遺伝性の出血疾患です。十分な量の第IX因子が無ければ、血液を凝固させて出血を効果的に塞ぐことができなくなります。主な症状として、関節内部での出血や、それに伴う関節痛・腫脹、紫斑、環状切除に伴う過剰出血、消化管・尿路からの出血、鼻血などがあります。主な治療法として、欠損した凝固因子の補充などがあります。

当レポートでは、世界各国でのB型血友病治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

B型血友病の概要

治療薬の開発

  • B型血友病向けパイプライン製品:概要
  • B型血友病向けパイプライン製品:比較分析

各企業で開発中のB型血友病治療薬

大学/研究機関で研究中のB型血友病治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

B型血友病治療薬:開発中の製品の一覧(企業別)

B型血友病治療薬:研究中の製品の一覧(大学/研究機関別)

B型血友病治療薬の開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • AstraZeneca Plc
  • Baxalta Incorporated
  • Bayer AG
  • Biogen, Inc.
  • Catalyst Biosciences, Inc.
  • CSL Limited
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Pharming Group N.V.
  • RegenxBio Inc.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.
  • Spark Therapeutics, Inc.
  • uniQure N.V.

B型血友病:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • albutrepenonacog alfa
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ALN-AT3
  • AMT-060
  • AZ-10047130
  • BAX-335
  • BAY-1093884
  • CB-2679d
  • CB-813d
  • B型血友病向け細胞療法
  • 第IX凝固因子(遺伝子組み換え型)
  • 第IX凝固因子(遺伝子組み換え型)
  • 第IX凝固因子FC(遺伝子組み換え型), Fc 融合タンパク質
  • 第VIIa凝固因子 (遺伝子組み換え型)
  • concizumab
  • CSL-689
  • DTX-101
  • B型血友病向け遺伝子療法
  • B型血友病向け第IX因子活性化用遺伝子療法
  • B型血友病向け第IX因子活性化用遺伝子療法
  • MOD-5014
  • MOD-9017
  • nonacog beta pegol
  • PF-06741086
  • SB-FIX
  • SPK-FIX
  • SVF-VIIa

B型血友病治療薬:パイプライン製品の最新動向

B型血友病治療薬:開発が休止状態の製品

B型血友病治療薬:開発が中止された製品

B型血友病関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7842IDB

Summary

Global Markets Direct's, 'Hemophilia B - Pipeline Review, H1 2016', provides an overview of the Hemophilia B pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hemophilia B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hemophilia B
  • The report reviews pipeline therapeutics for Hemophilia B by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hemophilia B therapeutics and enlists all their major and minor projects
  • The report assesses Hemophilia B therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hemophilia B

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hemophilia B
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hemophilia B pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemophilia B Overview
  • Therapeutics Development
    • Pipeline Products for Hemophilia B - Overview
    • Pipeline Products for Hemophilia B - Comparative Analysis
  • Hemophilia B - Therapeutics under Development by Companies
  • Hemophilia B - Therapeutics under Investigation by Universities/Institutes
  • Hemophilia B - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hemophilia B - Products under Development by Companies
  • Hemophilia B - Products under Investigation by Universities/Institutes
  • Hemophilia B - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Amarna Therapeutics B.V.
    • Baxalta Incorporated
    • Bayer AG
    • Biogen, Inc.
    • Catalyst Biosciences, Inc.
    • CSL Limited
    • Dimension Therapeutics, Inc.
    • Emergent BioSolutions Inc.
    • Novo Nordisk A/S
    • OPKO Health, Inc.
    • Pfizer Inc.
    • Pharming Group N.V.
    • RegenxBio Inc.
    • rEVO Biologics, Inc.
    • Sangamo BioSciences, Inc.
    • Spark Therapeutics, Inc.
    • UniQure N.V.
  • Hemophilia B - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AMT-060 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAX-335 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-1093884 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-2679d - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-813d - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • coagulation factor IX (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • coagulation factor IX (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • coagulation factor IX (recombinant), albumin fusion protein - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • coagulation factor IX (recombinant), Fc fusion protein - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • coagulation factor VIIa (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • concizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CSL-689 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DTX-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fitusiran - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LR-769 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-5014 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-9017 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nonacog beta pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-06741086 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-FIX - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPK-9001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SVF-VIIa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hemophilia B - Recent Pipeline Updates
  • Hemophilia B - Dormant Projects
  • Hemophilia B - Discontinued Products
  • Hemophilia B - Product Development Milestones
    • Featured News & Press Releases
      • Mar 21, 2016: IDELVION for Hemophilia B Now Available in the U.S.
      • Mar 04, 2016: FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B
      • Feb 29, 2016: IDELVION (rFIX-FP) - CHMP recommendation
      • Feb 26, 2016: Sobi and Biogen Receive Positive Opinion from CHMP for Alprolix (rFIXFc) for the Treatment of Hemophilia B
      • Feb 23, 2016: OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia
      • Feb 03, 2016: Biogen Announces The Availability Of ALPROLIX To Canadians With Hemophilia B
      • Jan 07, 2016: Novo Nordisk files for regulatory approval of long-acting factor IX in the EU for the treatment of hemophilia B
      • Dec 22, 2015: Sobi receives orphan drug designation for Alprolix in Switzerland
      • Dec 21, 2015: CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients
      • Dec 08, 2015: New Data Show ALPROLIX May Help Control Target Joint Bleeds in People with Hemophilia B
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hemophilia B, H1 2016
  • Number of Products under Development for Hemophilia B - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hemophilia B - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Hemophilia B - Pipeline by Amarna Therapeutics B.V., H1 2016
  • Hemophilia B - Pipeline by Baxalta Incorporated, H1 2016
  • Hemophilia B - Pipeline by Bayer AG, H1 2016
  • Hemophilia B - Pipeline by Biogen, Inc., H1 2016
  • Hemophilia B - Pipeline by Catalyst Biosciences, Inc., H1 2016
  • Hemophilia B - Pipeline by CSL Limited, H1 2016
  • Hemophilia B - Pipeline by Dimension Therapeutics, Inc., H1 2016
  • Hemophilia B - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Hemophilia B - Pipeline by Novo Nordisk A/S, H1 2016
  • Hemophilia B - Pipeline by OPKO Health, Inc., H1 2016
  • Hemophilia B - Pipeline by Pfizer Inc., H1 2016
  • Hemophilia B - Pipeline by Pharming Group N.V., H1 2016
  • Hemophilia B - Pipeline by RegenxBio Inc., H1 2016
  • Hemophilia B - Pipeline by rEVO Biologics, Inc., H1 2016
  • Hemophilia B - Pipeline by Sangamo BioSciences, Inc., H1 2016
  • Hemophilia B - Pipeline by Spark Therapeutics, Inc., H1 2016
  • Hemophilia B - Pipeline by UniQure N.V., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hemophilia B Therapeutics - Recent Pipeline Updates, H1 2016
  • Hemophilia B - Dormant Projects, H1 2016
  • Hemophilia B - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hemophilia B, H1 2016
  • Number of Products under Development for Hemophilia B - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top